Anavex Life Sciences Corp (AVXL)

[blu_1]

Biogen has a history of partnering up with lesser drug companies. For ex, it comarkets Tysabri (one of its 4 MS drugs) with Elan. Tysabri was Elan's drug more than 4 years ago.

From Wiki:
Elan Corporation, plc (NYSE:ELN) is pleased to announce the closing today of the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec. The agreement was announced on February 6, 2013. Under the terms of the agreement, Elan receives $3.25 billion in cash and will receive double digit tiered royalty payments, on all indications, for the life of the complete TYSABRI asset. For the first twelve months Elan will receive 12% royalties on in-market sales of TYSABRI, and thereafter, Elan will receive 18% royalties on in-market sales up to $2 billion and 25% royalties on in-market sales exceeding $2 billion. In 2012, in-market sales of TYSABRI were $1.6 billion.

Biogen also cosponsors another MS drug, Ampyra (dalfampridine). Its partner for that drug is Acorda Therapeutics. 2013 revenue was $302M.

As an aside, the name of one of Biogen's MS drugs is Avonex. Sounds strikingly similar to Anavex. Mere coincidence?